SSA
CNTA

Schonfeld Strategic Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-171,933
Closed -$6.83M – 2667
2026
Q1 		$6.83M Buy
+171,933
New +$4.4M 0.05% 401
2025
Q4 		– Sell
-172,696
Closed -$4.19M – 2121
2025
Q3 		$4.19M Buy
172,696
+54,533
+46% +$969K 0.02% 665
2025
Q2 		$1.55M Sell
118,163
-159,407
-57% -$2.02M 0.01% 1109
2025
Q1 		$3.99M Sell
277,570
-87,630
-24% -$1.43M 0.02% 613
2024
Q4 		$6.12M Buy
+365,200
New +$6.05M 0.04% 433
2024
Q3 		– Sell
-12,300
Closed -$111K – 2092
2024
Q2 		$111K Buy
+12,300
New +$117K ﹤0.01% 1878
2024
Q1 		– Sell
-12,629
Closed -$101K – 2114
2023
Q4 		$101K Buy
+12,629
New +$84.7K ﹤0.01% 1620

Schonfeld Strategic Advisors's CNTA Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 171,933 shares — an estimated $6.83M sold.

Schonfeld Strategic Advisors first reported a position in CNTA in Q4 2023 and held it in 7 quarters. The position peaked at $6.83M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 171,933 Centessa Pharmaceuticals shares in Q2 2026, an estimated $6.83M.
  • Schonfeld Strategic Advisors first reported a position in Centessa Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Centessa Pharmaceuticals position peaked at $6.83M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.